S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity

Journal of Rheumatology

Volumn 34, Issue 10, 2007, Pages 2089-2092

  Madland, Tor Magne ^a,b   Larsen, Annette ^a   Brun, Johan G ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarkers; Calprotectin; Psoriatic arthritis; S100A12; S100A8 S100A9

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALPROTECTIN; PROTEIN S 100; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSORIATIC ARTHRITIS;

ADULT; AGED; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; S100 PROTEINS; STATISTICS AS TOPIC;

EID: 35148832721     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii49-54.
2. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
3. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-68.
4. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-71.
5. Berntzen HB, Munthe E, Fagerhol MK. The major leukocyte protein L1 as an indicator of inflammatory joint disease. Scand J Rheumatol Suppl 1988;76:251-6.
6. Brun JG, Haga HJ, Boe E, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992;19:859-62.
7. Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994;21:733-8.
8. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 2003;48:1676-85.
9. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
10. Foell D, Kane D, Bresnihan B, et al. Expression of the proinflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology Oxford 2003;42:1383-9.
11. Rouleau P, Vandal K, Ryckman C, et al. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clin Immunol 2003;107:46-54.
12. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:R569-80.
13. Batliwalla FM, Li W, Ritchlin CT, et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005;11:21-9.
14. Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 2005;32:1918-22.
15. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
16. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
17. Kristinsson J, Roseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316-21.
18. Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen EK, Fagerhol MK. Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin. Scand J Immunol 2007;65:192-201.
19. Hammer HB, Syversen S, Ødegard S, Uhlig T, Landewé R, van der Heijde D. Calprotectin (a major leukocyte protein) in plasma predicts 10-year radiographic progression in patients with rheumatoid arthritis. EULAR. Amsterdam, 2006.
20. van Leeuwen MA, van Rijswijk MH, van der Heijde DM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993;32:9-13.
21. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-4.